Tenaya Therapeutics Newsroom

A Quick Look at Today's Ratings for Tenaya Therapeutics(TNYA.US), With a Forecast Between $6 to $19

Futu NewsDec 18 21:00 · Ratings

Tenaya Therapeutics Is Maintained at Buy by Chardan Capital

Dow JonesDec 18 19:15 · Ratings

Tenaya Therapeutics Analyst Ratings

BenzingaDec 18 17:51 · Ratings

Cautious Optimism for Tenaya Therapeutics' TN-201: Early Phase Study Shows Promising Efficacy and Safety

TipRanksDec 18 09:36

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

BenzingaDec 18 05:05

Update: Tenaya Shares Sink After Readout of Heart Disease Therapy Shows Manageable Safety Profile

MT NewswiresDec 18 04:58

Trending Stocks Today | Nukkleus Shoots up 871.22%

December 17th - US stocks trending in regular trading hours.Gainers: $Nukkleus(NUKK.US)$ surges 871.22% to $13.5 with a turnover of $1.09 billion. $Portage Biotech(PRTG.US)$ soars 170.76% to $8.8

Futu NewsDec 18 03:00

Optimistic Outlook on Tenaya Therapeutics' TN-201 Gene Therapy for Hypertrophic Cardiomyopathy

TipRanksDec 18 01:15

Express News | Tenaya Therapeutics Inc : Leerink Partners Cuts Target Price to $6 From $8

BreakingsDec 18 00:28

Tenaya in Selloff After Early-stage Data for Gene Therapy

Seeking AlphaDec 18 00:08

Tenaya Therapeutics Shares Are Trading Lower. The Company Announced Data From the First Cohort of Patients in the MyPEAK-1 Clinical Trial of TN-201 Gene Therapy.

BenzingaDec 17 22:59

Dow Dips Over 200 Points; US Retail Sales Top Estimates

BenzingaDec 17 22:46

Tenaya Therapeutics Reports Promising TN-201 Trial Results

TipRanksDec 17 21:17

Tenaya Therapeutics' Senior VP Resigns for New Opportunity

TipRanksDec 17 20:47

Express News | Tenaya Therapeutics Inc - Chihro Saito Resigns as Svp, Afo and Interim Pao of Tenaya

BreakingsDec 17 20:26

Tenaya Reports Early Results for Gene Therapy in Heart Disease

BenzingaDec 17 20:04

Express News | Tenaya Therapeutics Inc - Tn-201 Well Tolerated With Increasing Rna and Protein Levels

BreakingsDec 17 20:00

Tenaya Therapeutics To Announce Initial Data From MyPEAK-1 Phase 1b/2 Clinical Trial Of TN-201 Gene Therapy For MYBPC3-Associated Hypertrophic Cardiomyopathy On Dec. 17, 2024

BenzingaDec 17 05:34

Tenaya Therapeutics to Announce Initial Data From MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

GlobeNewswireDec 17 05:30

Express News | Tenaya Therapeutics to Announce Initial Data From Mypeak-1 Phase 1B/2 Clinical Trial of Tn-201 Gene Therapy for Mybpc3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

BreakingsDec 17 05:30